Industry

Seawolf launches with $100 million to develop DNA-based therapies

Seawolf raised $100 million to support research into DNA-based therapies.

Reported by 2 outlets Monday, November 16, 2026

A gloved hand using a pipette in a laboratory
Photo: Public domain

Seawolf Therapeutics emerged from stealth with $100 million in funding to support research into DNA-based therapies, BioPharma Dive reported. The San Diego startup's investors include Versant Ventures, MPM BioImpact, Eli Lilly, CRISPR Therapeutics and Novartis’ venture arm, according to the report. STAT also reported that Versant, Lilly and other investors are backing the company with $100 million.

Seawolf also disclosed a research collaboration and exclusive license agreement with Sanofi. The multi-target partnership will focus on therapies for bleeding disorders and other unnamed indications. Seawolf could receive up to $1.2 billion in milestone payments, plus tiered royalties on products resulting from the collaboration, BioPharma Dive reported.

The company said its TRIDENT platform uses lipid nanoparticles to deliver engineered DNA into cells. Seawolf said its lead program targets metabolic diseases and that the technology worked as intended in primate and mouse models of metabolic and rare diseases.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.